Both GLP-1 receptor agonists and SGLT2 inhibitors linked to reduced risk for ADRD, with no significant difference between them ...

Keytruda is a biologic that belongs to the programmed cell death protein 1 (PD-1) inhibitor drug class. Read on to learn about potential common, mild, and serious side effects of Keytruda.

GLP-1 RAs and SGLT2 inhibitors significantly reduce cardiovascular events and heart failure risk in older adults with type 2 diabetes compared to DPP-4 inhibitors. The study utilized health ...

So far, all that is known is that its lead programme carries a DAR8 topoisomerase-1 inhibitor payload and is scheduled to start clinical testing before the end of the year. The two following ADCs ...

PD-1 inhibitors belong to a class of medications known as immune checkpoint inhibitors, which have become an important part of many modern cancer treatment plans. PD-1 inhibitors work by helping ...

The discovery and preclinical efficacy of ANS-858, a proprietary, selective, reversible, orally bioavailable ALDH2 inhibitor will ... There are 1.2 million patients with cocaine use disorder ...

and may deliver increased efficacy in combination with other RAS/MAPK pathway inhibitors Approximately 20 percent of all cancers are driven by mutations of the RAS family of genes 1 Vividion continues ...

today announced that the first patient has been dosed with BBO-11818 in the Phase 1 KONQUER-101 trial for advanced solid tumors. BBO-11818 is an orally bioavailable small molecule dual inhibitor that ...

The article titled "Effects of the DPP-1 Inhibitor HSK31858 in Adults with Bronchiectasis in China (SAVE-BE): A Phase 2, Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial," focuses ...

with a unique binding mode from previously reported WRN inhibitors Phase 1 dose escalation trial ongoing in MSI-H solid tumors with GSK MSI-H prevalence has been reported at approximately 31% ...